Lineage Cell Therapeutics, Inc. (LCTX) income statement
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3019% above fair value
$0.77−0.05 (-5.87%)
Close on Nov 20, 2026Market cap $195.22MP/E –Yield –
Lineage Cell Therapeutics, Inc. financial ratios
See a number that looks wrong?